S&P US 500

IVV

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Little Green Pharma Ltd

LGP

Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. The company is headquartered in Perth, Western Australia. The company went IPO on 2020-02-20. Its principal activities include the cultivation of medicinal cannabis, procurement of raw materials and production of medicinal cannabis medicines; the supply of medicinal cannabis products into Australia and Europe; the supply of medicinal cannabis products for observational and clinical studies and research and development of new medicinal cannabis products, and the development of a psychedelics business including sponsoring a clinical trial into the treatment of refractory depression with psilocybin assisted therapy, construction of a psilocybin mushroom cultivation facility, and establishment of a psychedelic treatment clinic. The company has two global production sites for the manufacture of its own-branded and white-label ranges medicinal cannabis products.

NASDAQ US 100

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

Zelira Therapeutics Limited

ZLD

Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. The company owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. The company has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

Avecho Biotechnology Limited

AVENA

Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm develops and commercializes human and animal health products using its drug delivery system Tocopherol Phosphate Mixture (TPM). The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, Daptomycin, Propofol and Veterinary Applications. The firm's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Company’s Human Health segment covers delivery of pharmaceutical products through gels, injectables and patches. This segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. The firm is also developing TPM to enhance feed efficiency and health of livestock. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.